[go: up one dir, main page]

AR025330A1 - Combinacion de sustancias activas con clonidina - Google Patents

Combinacion de sustancias activas con clonidina

Info

Publication number
AR025330A1
AR025330A1 ARP000104292A ARP000104292A AR025330A1 AR 025330 A1 AR025330 A1 AR 025330A1 AR P000104292 A ARP000104292 A AR P000104292A AR P000104292 A ARP000104292 A AR P000104292A AR 025330 A1 AR025330 A1 AR 025330A1
Authority
AR
Argentina
Prior art keywords
clonidine
combination
active substances
pramipezole
medicine
Prior art date
Application number
ARP000104292A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of AR025330A1 publication Critical patent/AR025330A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Combinacion de sustancias activas, que consta de clonidina y pramipezol, para el tratamiento del síndrome de piernas inquietas y uso para la preparacionde un medicamento.
ARP000104292A 1999-08-19 2000-08-18 Combinacion de sustancias activas con clonidina AR025330A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19938825A DE19938825A1 (de) 1999-08-19 1999-08-19 Wirkstoffkombination mit Clonidin

Publications (1)

Publication Number Publication Date
AR025330A1 true AR025330A1 (es) 2002-11-20

Family

ID=7918574

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104292A AR025330A1 (es) 1999-08-19 2000-08-18 Combinacion de sustancias activas con clonidina

Country Status (19)

Country Link
US (1) US20020010201A1 (es)
EP (1) EP1210081A2 (es)
JP (1) JP2003507420A (es)
KR (1) KR20020060163A (es)
AR (1) AR025330A1 (es)
AU (1) AU6440600A (es)
BR (1) BR0013353A (es)
CA (1) CA2376606A1 (es)
CO (1) CO5200840A1 (es)
CZ (1) CZ2002515A3 (es)
DE (1) DE19938825A1 (es)
IL (1) IL147741A0 (es)
MX (1) MXPA02001138A (es)
NO (1) NO20020793L (es)
PE (1) PE20010642A1 (es)
PL (1) PL353358A1 (es)
TR (1) TR200200449T2 (es)
UY (1) UY26293A1 (es)
WO (1) WO2001013902A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP2305252A1 (en) 2001-12-11 2011-04-06 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
CN1671390A (zh) 2002-08-30 2005-09-21 协和发酵工业株式会社 用于治疗多动腿综合症或相关疾病的腺苷a2a受体拮抗剂
PT1426049E (pt) * 2002-12-02 2005-09-30 Sanol Arznei Schwarz Gmbh Administracao iontoforetica de rotigotina para o tratamento da doenca de parkinson
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
KR20090021169A (ko) 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
WO2008009664A2 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． キラル精製置換ベンゾチアゾールジアミンの合成
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US20150342899A1 (en) * 2012-12-28 2015-12-03 Noven Pharmaceuticals, Inc. Compositions and methods for transdermal delivery of amphetamine and clonidine
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
US6001861A (en) * 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
AU3490300A (en) * 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Also Published As

Publication number Publication date
MXPA02001138A (es) 2002-10-31
KR20020060163A (ko) 2002-07-16
IL147741A0 (en) 2002-08-14
BR0013353A (pt) 2002-04-23
NO20020793D0 (no) 2002-02-18
NO20020793L (no) 2002-02-18
WO2001013902A2 (de) 2001-03-01
CA2376606A1 (en) 2001-03-01
CZ2002515A3 (cs) 2002-05-15
JP2003507420A (ja) 2003-02-25
EP1210081A2 (de) 2002-06-05
UY26293A1 (es) 2001-04-30
PE20010642A1 (es) 2001-06-08
PL353358A1 (en) 2003-11-17
TR200200449T2 (tr) 2002-08-21
DE19938825A1 (de) 2001-04-26
WO2001013902A3 (de) 2001-08-23
US20020010201A1 (en) 2002-01-24
AU6440600A (en) 2001-03-19
CO5200840A1 (es) 2002-09-27

Similar Documents

Publication Publication Date Title
AR025330A1 (es) Combinacion de sustancias activas con clonidina
AR025329A1 (es) Tratamiento medicamentoso del sindrome de piernas inquietas
SV1995000045A (es) Benzoxazolil- y benzotiazoliloxazolidinonas, ref. le a 30616-sv
AR010385A1 (es) Compuesto derivado de propiofenona, proceso para su preparacion, composicion farmaceutica que lo contiene y uso de dicho compuesto.
AR037109A1 (es) Uso de flibanserina
CL2004000675A1 (es) Uso de una combinacion de androgeno de origen biogenico o sintetico y un estrogeno de origen biogenico o sintetico para preparar un medicamento util en el tratamiento del hipogonadismo y enfermedades hipofisis o glandula pituitaria en hombres, para e
ES2152222T3 (es) Sulfonamidas, su preparacion y su uso como medicamento e intermedio.
AR031975A1 (es) Compuestos analogos de (1r,cis)-4-(6-amino-9h-purin-9-il) -2-ciclopenteno-1-metanol, proceso para su preparacion, su uso en el tratamiento de infecciones virales, y envase que los contiene
CY1112361T1 (el) Σκευασματα για αντικαρκινικη θεραπεια που περιεχουν εκτεϊνασκιδινη 743
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
DE59902006D1 (de) Wirkstoffhaltige aromatische copolyester
ES2175798T3 (es) Cd8 como un inhibidor del sistema inmunitario celular.
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
SE9701161D0 (sv) New use I
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
AR023597A1 (es) Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion delconjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos ansiedad-depresion
UY29952A1 (es) Composiciones faramacéuticas que comprenden 4-(4-fluoro-2-metil-1h-indol-5-iloxi)-6-metoxi-7-(3-(pirrolidin-1-il)propoxi)quinazolina o una sal farmacéuticamente aceptable del mismo, procesos de preparación y uso
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
ES2193007T1 (es) Formulacion farmaceutica estable que comprende la modificacion ii de torsemida.
PE20011080A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839